These results suggest the potential therapeutic benefit of targeting GAS5 for the treatment of neurological disorders associated with microglial polarization, including MS, Alzheimer's disease, and Parkinson's disease. The gene discussed is GAS5; the disease is early-onset autosomal dominant Alzheimer disease.